Article
Pyott reappointed
The board of directors of Allergan has reappointed David E.I. Pyott as president, effective March 27. Pyott? who previously served as president from 1998 until 2006 ? also will continue to serve Allergan in his current roles as chairman of the board and chief executive officer. Pyott's role as president is not an interim position, and Allergan does not plan to name a new president.
Irvine, CA-The board of directors of Allergan has reappointed David E.I. Pyott as president, effective March 27.
Pyott-who previously served as president from 1998 until 2006-also will continue to serve Allergan in his current roles as chairman of the board and chief executive officer (CEO). Pyott’s role as president is not an interim position, and Allergan does not plan to name a new president.
Pyott succeeds F. Michael Ball, who has accepted the position of CEO of Hospira, a specialty pharmaceutical and medication delivery company based in Lake Forest, IL.
According to Allergan, Pyott expanding his role as president will allow for a seamless management transition and continuity in execution of Allergan’s established strategies. It also will allow Pyott to invest more of his efforts in the development of the strong bench of Allergan leaders and their teams.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
